CINOBAC
LOE ApproachingNDAORALCAPSULE
Approved
Jun 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CINOBAC is an oral small-molecule antibiotic capsule approved by Eli Lilly in 1980. The specific indication and mechanism of action are not documented in available data. This legacy product represents a mature antibiotic therapy in the oral delivery space.
LOE Approaching
Product approaching loss of exclusivity with minimal current linked job openings suggests a declining commercial footprint and likely reduced team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CINOBAC represents a late-career opportunity focused on lifecycle management, generic defense, and cost optimization rather than growth or innovation. Limited headcount and job openings suggest this product is in maintenance or wind-down mode at Eli Lilly.
Brand Manager (lifecycle management)Field Sales (consolidation phase)
Worked on CINOBAC at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.